Astrazeneca's breast cancer drug fails late-stage trial

AstraZeneca ​said on ‌Friday ​its ​breast cancer ⁠drug ​failed to ​meet the ​main ​goal of improving ‌progression-free ⁠survival during ​a ​late-stage ⁠trial.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。